Kết quả tìm kiếm - Dickran Kazandjian

Tinh chỉnh kết quả
  1. 1
    Multiple myeloma epidemiology and survival: A unique malignancy

    Multiple myeloma epidemiology and survival: A unique malignancy Bằng Dickran Kazandjian

    Được phát hành 2016
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

    A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival Bằng Dickran Kazandjian, Ola Landgren

    Được phát hành 2016
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer Bằng Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

    Được phát hành 2019
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

    Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions Bằng Mina Meseha, James E. Hoffman, Dickran Kazandjian, Ola Landgren, Benjamin Diamond

    Được phát hành 2024
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Second malignancies in multiple myeloma; emerging patterns and future directions

    Second malignancies in multiple myeloma; emerging patterns and future directions Bằng Kylee Maclachlan, Benjamin Diamond, Francesco Maura, Jens Hillengaß, Ingemar Turesson, Ola Landgren, Dickran Kazandjian

    Được phát hành 2020
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

    Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer Bằng Dickran Kazandjian, Gideon M. Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven J. Lemery, Richard Pazdur

    Được phát hành 2016
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

    FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements Bằng Dickran Kazandjian, Gideon M. Blumenthal, Huanyu Chen, Kun He, Mona Patel, Robert Justice, Patricia Keegan, Richard Pazdur

    Được phát hành 2014
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

    Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma Bằng Mattias Carlsten, Neha Korde, Ritesh R. Kotecha, Robert Reger, Simona Bor, Dickran Kazandjian, Ola Landgren, Richard W. Childs

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy Bằng Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

    Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration... Bằng Gideon M. Blumenthal, Stella Karuri, Hui Zhang, Lijun Zhang, Sean Khozin, Dickran Kazandjian, Shenghui Tang, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    Được phát hành 2015
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy Bằng Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Shenghui Tang, Meredith Libeg, Paul G. Kluetz, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    Được phát hành 2015
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials

    Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials Bằng Gideon M. Blumenthal, Lijun Zhang, Hui Zhang, Dickran Kazandjian, Sean Khozin, Shenghui Tang, Kirsten B. Goldberg, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    Được phát hành 2017
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy Bằng Caroline E. McCoach, Gideon M. Blumenthal, L. Zhang, Adrian Myers, Shenghui Tang, R. Sridhara, Patricia Keegan, Richard Pazdur, Robert C. Doebele, Dickran Kazandjian

    Được phát hành 2017
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

    Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients Bằng Dickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, Even H. Rustad, Venkata Yellapantula, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alex Dew, Elli Papaemmanuil, Irina Marić, Mary Kwok, Ola Landgren

    Được phát hành 2019
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry

    The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry Bằng Hemant Kulkarni, Vincent C. Marconi, Weijing He, Michael L. Landrum, Jason F. Okulicz, Judith Delmar, Dickran Kazandjian, John Castiblanco, Seema S. Ahuja, Edwina Wright, Robin A. Weiss, Robert A. Clark, Matthew J. Dolan, Sunil K. Ahuja

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

    Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis Bằng Kelly J. Norsworthy, Flora Mulkey, Emma C. Scott, Ashley F. Ward, Donna Przepiorka, Rosane Charlab, Sarah E. Dorff, Albert Deisseroth, Dickran Kazandjian, Rajeshwari Sridhara, Julia A. Beaver, Ann T. Farrell, R. Angelo de Claro, Richard Pazdur

    Được phát hành 2020
    lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer

    Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer Bằng Ewy A. Mathé, Andrew D. Patterson, Majda Haznadar, Soumen Manna, Kristopher W. Krausz, Elise D. Bowman, Peter G. Shields, Jeffrey R. Idle, Philip B. Smith, Katsuhiro Anami, Dickran Kazandjian, Emmanuel Hatzakis, Frank J. Gonzalez, Curtis C. Harris

    Được phát hành 2014
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma

    Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma Bằng Ichiro Akagi, Hirokazu Okayama, Aaron J. Schetter, Ana I. Robles, Takashi Kohno, Elise D. Bowman, Dickran Kazandjian, Judith A. Welsh, Naohide Oue, Motonobu Saito, Masao Miyashita, Eiji Uchida, Toshihiro Takizawa, Seiichi Takenoshita, Vidar Skaug, Steen Mollerup, Aage Haugen, Jun Yokota, Curtis C. Harris

    Được phát hành 2013
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Extreme body mass index and survival in newly diagnosed multiple myeloma patients

    Extreme body mass index and survival in newly diagnosed multiple myeloma patients Bằng Urvi A. Shah, Karissa Whiting, Sean M. Devlin, Rachel Ershler, Bindu Kanapuru, David Jungpa Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M. Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M. Birmann, Saad Z. Usmani, Nicole Gormley, Catherine R. Marinac, Ola Landgren

    Được phát hành 2023
    lấy văn bản lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

    Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Bằng Ola Landgren, Jonathan N. Hofmann, Charlene M. McShane, Loredana Santo, Malin Hultcrantz, Neha Korde, Sham Mailankody, Dickran Kazandjian, Murata Kazunori, Katie Thoren, Lakshmi V. Ramanathan, Ahmet Doǧan, Even H Rustad, Sydney X. Lu, Theresia Akhlaghi, Sigurður Y. Kristinsson, Magnus Björkholm, Sean M. Devlin, Mark P. Purdue, Ruth M. Pfeiffer, Ingemar Turesson

    Được phát hành 2019
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: